✦ LIBER ✦

A randomized open label study comparing first-line treatment with bosentan or sildenafil in Pulmonary Arterial Hypertension (PAH)

✍ Scribed by Mazzanti, G.; Albini, A.; Palazzini, M.; Monti, E.; Bachetti, C.; Rinaldi, A.; Conficoni, E.; Manes, A.; Branzi, A.; Galie', N.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

[American Thoracic Society American Thor

✍ Mazzanti, Gaia; Palazzini, Massimiliano; Leci, Enri; Dardi, Fabio; Rinaldi, Andr 📂 Article 📅 2012 🏛 American Thoracic Society ⚖ 20 KB

[American Thoracic Society American Thor

✍ Palazzini, Massimiliano; Mazzanti, Gaia; Gotti, Enrico; Bulatovic, Ivana; Manes, 📂 Article 📅 2010 🏛 American Thoracic Society ⚖ 24 KB

The effect of open label UT15 or bosenta

✍ A.M Keogh; K.M Brown; C.A Corrigan; C Allada; Y Ten 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 77 KB

Treatment Outcomes in Pulmonary Arterial

✍ Crackett, R.M.; Hall, A.; Day, M.B.; Desoyza, J.R.; Small, T.; Fisher, A.J.; Lor 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 82 KB

Two formulations of epoprostenol sodium

✍ Chin, Kelly M.; Badesch, David B.; Robbins, Ivan M.; Tapson, Victor F.; Palevsky 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 603 KB

A Randomized, Open-Label, 3-Way Crossove

✍ Gao, X.; O'Gorman, M.; Cook, J.; Shi, H.; LaBadie, R. R. 📂 Article 📅 2012 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 260 KB